Publications

Anthracyclines are among the most widely used chemotherapy drugs and have been a mainstay of cancer treatment for more than 30 years. Their extraordinary efficacy against numerous solid and hematologic tumors means that they remain first-line drugs today, administered alone or in combination with other therapies. Anthracyclines continue to be

Colorectal cancer is the third most common cancer and second leading cause of cancer-related death worldwide. Standard management of stage III or high-risk stage II colon cancer includes surgery followed by 3 to 6 months of treatments. Despite these treatments, recurrent disease develops in 20 to 40% of the patients.

Anthracyclines, alone or in combination, remain the first-line therapy for many cancers, including various forms of lymphoma, breast cancer, leukaemia, melanoma, and uterine and gastric cancers. Every year, anthracyclines are administered to >3 million European citizens to treat a first cancer. The curative potential of anthracycline therapy is determined by

GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through

This article is authored by 2 PIs of RESILIENCE (María Gomes-Silva from IPO Lisbon & Borja Ibanez from CNIC Spain). This editorial summarizes the results of the 2 first trials testing remote ischemic conditioning in the context of anthracycline cardiotoxicity. In this article, the 2 trials are described and their